January 24, 2025 8:25am
When you’re riding’ ahead in your portfolio, take a look back every now and then to make sure your stocks are moving
Keep a buy ticket in one hand and a finger on the sell button
Pre-open Indications: 4 Positive, 4 Negative and 1 Sell into Strength
Never leave an investor uninform
Remember that overnight and pre-open actions’ futures and markets doesn’t necessarily translate into actual trading in today’s market session.
My interpretation of the morning’s numbers is written to be informative; it’s built on what happened to make “it” happen today!
Thursday’s night’s … RegMed Investors (RMi) Closing Bell: How investors can best navigate the sector ahead … https://www.regmedinvestors.com/articles/13777
Friday; the pre-open Dow futures are DOWN -0.24% or (-107 points), the S&P futures are DOWN -0.12% or (-7 points) and the Nasdaq futures are DOWN -0.06% or (-12 points)
- Futures are down and little changed, Friday. 1/24/25
- Europe markets trade higher,
- Asia-Pacific markets climbed Friday.
Henry’omics: We need to more than consider the economic environment to comprehend the micro re “our” universe of cell and gene therapy companies
Thursday: The Dow closed UP +408.34 points or +0.92%, the S&P closed UP +32.34 points or +0.53% while the Nasdaq closed UP +44.34 points or +0.22%
For the week so far, Dow is up +2.5% and S&P 500 h gained +2%, respectively while the Nasdaq is up about 2.2%.
Economic Data Docket: S&P Global US manufacturing PMI, January preliminary (49.4 prior); S&P Global Services PMI, January preliminary (56.8 prior); S&P Global US composite PMI, January (55.4 prior); University of Michigan consumer sentiment, January final (73.2 prior); Existing home sales, December (1.2% expected, 4.8% prior)
Q1/25: January – 2 holidays, 1 market close, 5 negative and 9 positive closes
- Q4/24: December 1 holiday, 15 negative and 5 positive closes
- November 10 negative and 9 positive closes
- October: 8 positive and 15 negative closes
Companies in my headlights – It’s your decision; I provide ideas and context
I post about “indication intelligence” looking toward investment conferences … to assist investors with insight into sector vulnerabilities and strengths. A dictionary definition of “indicate” refers to something less than a certainty; an indication could be a signal of being oversold or overbought, a recommendation, or grounds for inferring or a basis for believing.
Yet again, I am passing on forecasting the daily indications as expectations are in focus as expectation in the aftermarket fluctuated while the pre-open awaits … it is still a mix of ups, downs and just unknowns.
Yet, watch …
Sell into Strength: Mesoblast (MESO),
Negative --- Alnylam Pharmaceutics (ALNY), uniQure NV (QURE), BioLife Solutions (BLFS), Vericel (VCEL), AxoGen (AXGN)
Positive Moderna (MRNA), Lenz Therapeutics (LENZ), Blueprint Medicine (BPMC), Ionis Pharmaceuticals (IONS), Solid Biosciences (SLDB)
The BOTTOM LINE: The RegMed sector suffers the tourist routine … most traders hear a piece of news, contemplate a pumping to buy and a dumping to sell. These same buyers/sellers can also be very fickle as their purchasing habits are often based on emotion, not sound investment strategies.
These are the best of times and the worst of times.
- Expect volatility to be more the norm versus exception.
- Short term, markets and the cell and gene therapy sector will have to contend with upcoming earnings reports as the usual reporting pushes into the “dump.”
Two trading days into Trump new administration, the newly sworn-in president is already having an impact on the stock market. More and more needed!!
Earnings are a-comin’ … from Q4/24 are due … as downdrafts follow as proven in past sessions!
- Big Point to remember “Think about it; the biggest problem the cell and gene therapy sector has … 99% of them have no earnings! If rates are higher for longer, that means that sector companies will continue to struggle or be unable to raise capital and therefore be subject to debt servicing firms!” <Me>
What could 2025 have in store for the capital access space as Partners are the gift of life!
- "You'll see a number of cell and gene therapy comandantes drive for secondaries – they’re desperate for cash, but I do think a lot of cell and gene therapy sector companies NEED to be focused on what is driving their own growth —they're focused on a lot of change BUT … that's happening in the market… capital expansion is second.
I seem to be asking a question followed by a question …
- Do we need to brace ourself for more economics and their down trending affect?
- Is this market STILL “bubblicious” my concerns are macroeconomic and valuation
Welcome to my world of defining the “grey’ in our universe!
- The sector is what it is, until it isn’t and even then, it doesn’t seem to be… as NOT much changes as the sector’s share pricing rides the waves of volatility, algorithms, electronic trading and short covering.
- I am more frequently right than consequentially wrong; if I wanted to be liked, I wouldn’t have been an analyst/journalist.
Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice. All investments are subject to risks. Investors should consider investment objectives.
Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors. All investments are subject to risks. Investors should consider investment objectives. Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and it’s or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.
Henry McCusker, the editor and publisher of RegMed Investors could hold or have positions securities referred to in this publication and he will NOTIFY investors of holdings.